Seroquel XR defendants must face ‘supply option’ claims in US antitrust dispute
Allegations of Sherman Act violations in connection with a 2011 patent settlement where AstraZeneca agreed to supply Handa with generic extended-release quetiapine fumarate — the active ingredient in anti-psychotic drug Seroquel...To view the full article, register now.
Already a subscriber? Click here to view full article